DARS™ Stock Ratings for BMY

If you were a Dividend.com Premium member, you would be seeing detailed DARS™ Dividend Stock Ratings information for Bristol-Myers Squibb (BMY) in this space. Sign up for Dividend.com Premium today to gain access to ratings on nearly 2,000 dividend-paying stocks, exclusive members-only articles, historical dividend information, and more!

Subscribe to Dividend.com Premium Today! »

Recent Dividend.com Articles for BMY

• Bristol Myers Price Target, Earnings Estimate Raised at Barclays Capital (BMY)
  Tue, Nov 17, 2009
• Market Wrap-Up for Nov.16 (BA, BLK, BMY, LOW, STT, more)
  Mon, Nov 16, 2009
• Bristol Myers Spinning off Mead Johnson Nutrition (BMY)
  Mon, Nov 16, 2009
• Bristol Myers Q3 Profit Beats View, Revenue Rises (BMY)
  Thu, Oct 22, 2009
• Bristol Myers Initiated as "Outperform" at Wells Fargo (BMY)
  Fri, Oct 9, 2009
• Latest Dividend Notes (MCD, KFT, MMM, BMY, JNJ, ABT, NVS, more)
  Wed, Sep 30, 2009
• Market Wrap-Up for Aug.28
  Fri, Aug 28, 2009
• Two New Dividend Stocks Added to Recommended List
  Mon, Aug 24, 2009
• Top Large Cap Dividend Stock Prospects - August 22 Edition
  Sat, Aug 22, 2009
• Bristol Myers Q2 Profit Rises 29%, Announces Medarex Acquisition (BMY)
  Thu, Jul 23, 2009
• ActiveStocks.com Morning Playbook
  Thu, Jul 23, 2009
• ActiveStocks.com - Paul's Playbook
  Wed, Jul 15, 2009
• 4 Dividend Stocks Removed from Recommended List
  Wed, Jun 10, 2009
• Two Dividend Stocks Removed from Recommended List
  Fri, May 22, 2009
• Bristol-Myers Q1 Profit Falls, but Sales Increase (BMY)
  Tue, Apr 28, 2009
• This Week's Playbook for Apr.27-May 1
  Sat, Apr 25, 2009
• Market Wrap for Apr.24
  Fri, Apr 24, 2009
• Bristol-Myers Wins Albilify Extension Through 2012, Reaffirms 2009 Guidance (BMY)
  Mon, Apr 6, 2009
• Market Wrap-Up for Jan.27
  Tue, Jan 27, 2009

Company Profile & Recommendation

Company Profile

Bristol-Myers Squibb (BMY)- another pharmaceutical that has had issues the last few years with a thinning drug pipeline, but the yield is attractive. Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals, and related health care products worldwide. Some of it's pharmaceuticals brands include Plavix, Pravacol, Coudamin, and Monopril; virology products comprising Reyataz, Sustiva, Zerit, and Baraclude; oncology products comprising Erbitux, Taxol, and Sprycel; affective and other psychiatric disorder products, such as Abilify and Emsam; immunoscience products comprising Orencia; other infectious diseases products comprising Cefzil; and other pharmaceutical products that primarily include Efferalagan. The company's Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising Enfamil products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company was founded in 1887. It was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989.

* Stock price reflects previous day's closing price. All stock quotes on this website should be considered as having a 24-hour delay.

** Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. The author is not registered as an investment adviser. The author may or may not hold positions in the securities mentioned in this article or video. The author relies upon the "publisher's exclusion" from the definition of "investment adviser" as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

*** All dividend payout and date information on this website is for information purposes only. We do not guarantee the accuracy of any dividend dates or payout amounts. Always check with your broker first before purchasing any security.